References
1-) Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and
COVID-19. Nat Rev Microbiol. 2021;19:141-154. doi:
10.1038/s41579-020-00459-7.
2-)
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
3-) Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of
Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in
Wuhan, China. JAMA Cardiol. 2020;5:802-810. doi:
10.1001/jamacardio.2020.0950
4-) Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J,
Felix SB, et al. Current state of knowledge on aetiology, diagnosis,
management, and therapy of myocarditis: a position statement of the
European Society of Cardiology Working Group on Myocardial and
Pericardial Diseases. Eur Heart J. 2013;34:2636-48, 2648a-2648d. doi:
10.1093/eurheartj/eht210.
5-) Modin D, Claggett B, Sindet-Pedersen C, Lassen MCH, Skaarup KG,
Jensen JUS, et al. Acute COVID-19 and the Incidence of Ischemic Stroke
and Acute Myocardial Infarction. Circulation. 2020;142:2080-2082. doi:
10.1161/CIRCULATIONAHA.120.050809.
6-) Bangalore S, Sharma A, Slotwiner A, Yatskar L, Harari R, Shah B, et
al. ST-Segment Elevation in Patients with Covid-19 - A Case Series. N
Engl J Med. 2020;382:2478-2480. doi: 10.1056/NEJMc2009020.
7-) Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J,
Berger JS. Thrombosis in Hospitalized Patients With COVID-19 in a New
York City Health System. JAMA. 2020;324:799-801. doi:
10.1001/jama.2020.13372.
8-) Sandoval Y, Januzzi JL Jr, Jaffe AS. Cardiac Troponin for Assessment
of Myocardial Injury in COVID-19: JACC Review Topic of the Week. J Am
Coll Cardiol. 2020;76:1244-1258. doi: 10.1016/j.jacc.2020.06.068.
9-) Fox SE, Lameira FS, Rinker EB, Vander Heide RS. Cardiac
Endotheliitis and Multisystem Inflammatory Syndrome After COVID-19. Ann
Intern Med. 2020;173:1025-1027. doi: 10.7326/L20-0882.
10-) Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R,
Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in
COVID-19. Lancet. 2020; 395:1417-1418. doi:
10.1016/S0140-6736(20)30937-5.
11-) Barbato E, Aarnoudse W, Aengevaeren WR, Werner G, Klauss V, Bojara
W, et al. Validation of coronary flow reserve measurements by
thermodilution in clinical practice. Eur Heart J. 2004;25:219-23. doi:
10.1016/j.ehj.2003.11.009.
12-) Lanza GA, Buffon A, Sestito A, Natale L, Sgueglia GA, Galiuto L, et
al. Relation between stress-induced myocardial perfusion defects on
cardiovascular magnetic resonance and coronary microvascular dysfunction
in patients with cardiac syndrome X. J Am Coll Cardiol. 2008;51:466-72.
doi: 10.1016/j.jacc.2007.08.060.
13-) Murthy VL, Naya M, Taqueti VR, Foster CR, Gaber M, Hainer J, et al.
Effects of sex on coronary microvascular dysfunction and cardiac
outcomes. Circulation. 2014;129:2518-27. doi:
10.1161/CIRCULATIONAHA.113.008507.
14-) Galiuto L, Sestito A, Barchetta S, Sgueglia GA, Infusino F, La Rosa
C, et al. Noninvasive evaluation of flow reserve in the left anterior
descending coronary artery in patients with cardiac syndrome X. Am J
Cardiol. 2007;99:1378-83. doi: 10.1016/j.amjcard.2006.12.070.
15-) Caliskan M, Turan Y, Caliskan Z, et al. Previous gestational
diabetes history is associated with impaired coronary flow reserve. Ann
Med. 2015;47:615–623. doi:10.3109/07853890.2015.1099719
16-) Ciftci FC, Caliskan M, Ciftci O, et al. Impaired coronary
microvascular function and increased intima-media thickness in
preeclampsia. J Am Soc Hypertens. 2014;8:820–826.
doi:10.1016/j.jash.2014.08.012
17-) Lowenstein CJ, Solomon SD. Severe COVID-19 Is a Microvascular
Disease. Circulation. 2020;142:1609-1611. doi:
10.1161/CIRCULATIONAHA.120.050354.
18-) Landecho MF, Yuste JR, Gándara E, Sunsundegui P, Quiroga J, Alcaide
AB, et al. COVID-19 retinal microangiopathy as an in vivo biomarker of
systemic vascular disease? J Intern Med. 2021;289:116-120. doi:
10.1111/joim.13156.
19-) Carsetti A, Damiani E, Casarotta E, Scorcella C, Domizi R,
Montomoli J, et al. Sublingual microcirculation in patients with
SARS-CoV-2 undergoing veno-venous extracorporeal membrane oxygenation.
Microvasc Res. 2020;132:104064. doi: 10.1016/j.mvr.2020.104064.
20-) Yin J, Wang S, Liu Y, Chen J, Li D, Xu T. Coronary microvascular
dysfunction pathophysiology in COVID-19. Microcirculation. 2021:e12718.
doi: 10.1111/micc.12718.
21-) Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T,
Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA,
Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2
and Is Blocked by a Clinically Proven Protease Inhibitor. Cell.
2020;181:271-280.e8. doi: 10.1016/j.cell.2020.02.052.
22-) Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H.
Tissue distribution of ACE2 protein, the functional receptor for SARS
coronavirus. A first step in understanding SARS pathogenesis. J Pathol.
2004;203:631-7. doi: 10.1002/path.1570.
23-) Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R,
Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in
COVID-19. Lancet. 2020;395:1417-1418. doi:
10.1016/S0140-6736(20)30937-5.
24-) Bearse M, Hung YP, Krauson AJ, Bonanno L, Boyraz B, Harris CK, et
al. Factors associated with myocardial SARS-CoV-2 infection,
myocarditis, and cardiac inflammation in patients with COVID-19. Mod
Pathol. 2021;34:1345-1357. doi: 10.1038/s41379-021-00790-1.
25-) Bösmüller H, Traxler S, Bitzer M, Häberle H, Raiser W, Nann D, et
al. The evolution of pulmonary pathology in fatal COVID-19 disease: an
autopsy study with clinical correlation. Virchows Arch.
2020;477:349-357. doi: 10.1007/s00428-020-02881-x.
26-) Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers D, Kant
KM, et al. Confirmation of the high cumulative incidence of thrombotic
complications in critically ill ICU patients with COVID-19: An updated
analysis. Thromb Res. 2020;191:148-150. doi:
10.1016/j.thromres.2020.04.041.
27-) O’Sullivan JM, Gonagle DM, Ward SE, Preston RJS, O’Donnell JS.
Endothelial cells orchestrate COVID-19 coagulopathy. Lancet Haematol.
2020;7:e553-e555. doi: 10.1016/S2352-3026(20)30215-5.
28-) Karakike E, Giamarellos-Bourboulis EJ. Macrophage Activation-Like
Syndrome: A Distinct Entity Leading to Early Death in Sepsis. Front
Immunol. 2019;10:55. doi: 10.3389/fimmu.2019.00055.
29-) Abou-Arab O, Beyls C, Khalipha A, Guilbart M, Huette P, Malaquin S,
et al. Microvascular flow alterations in critically ill COVID-19
patients: A prospective study. PLoS One. 2021;16:e0246636. doi:
10.1371/journal.pone.0246636.
30-) Tehrani S, Gille-Johnson P. Microvascular Dysfunction in Patients
with Critical COVID-19, A Pilot Study. Shock. 2021 May 4. doi:
10.1097/SHK.0000000000001803.
31-) Sabioni L, De Lorenzo A, Lamas C, Muccillo F, Castro-Faria-Neto HC,
Estato V, et al. Systemic microvascular endothelial dysfunction and
disease severity in COVID-19 patients: Evaluation by laser Doppler
perfusion monitoring and cytokine/chemokine analysis. Microvasc Res.
2021;134:104119. doi: 10.1016/j.mvr.2020.104119.
32-) Hoffman JI. Problems of coronary flow reserve. Ann Biomed Eng. 2000
Aug;28(8):884-96. doi: 10.1114/1.1308503. PMID: 11144672.
33-) Escher F, Pietsch H, Aleshcheva G, Bock T, Baumeier C, Elsaesser A,
et al. Detection of viral SARS-CoV-2 genomes and histopathological
changes in endomyocardial biopsies. ESC Heart Fail. 2020;7:2440-2447.
doi: 10.1002/ehf2.12805.
34-) Park JH, Moon JY, Sohn KM, Kim YS. Two Fatal Cases of
Stress-induced Cardiomyopathy in COVID-19 Patients. J Cardiovasc
Imaging. 2020;28:300-303. doi: 10.4250/jcvi.2020.0125.